Literature DB >> 10881031

Nicotine-induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid.

S Erhardt1, M Hajos, A Lindberg, G Engberg.   

Abstract

The present electrophysiological study shows that manipulation with endogenous brain kynurenic acid (KYNA) is able to affect the response of central noradrenergic neurons to nicotine. Previous studies have shown that systemically administered nicotine in low doses is associated with a marked, but short-lasting increase in the firing rate of rat noradrenergic neurons in the locus coeruleus (LC). This action of nicotine is of peripheral origin and finally mediated via a release of glutamate within the LC. KYNA is an endogenous glutamate receptor antagonist, which shows an uneven distribution in human brain. Previous studies have shown that a potent inhibitor of kynurenine 3-hydroxylase, PNU 156561A, is able to dose-dependently increase the levels of KYNA in brain. Anesthetized rats were given PNU 156561A in a dose that caused a 5-fold increase in brain KYNA levels after 3-6 hours (40 mg/kg, i.v. ). This treatment was found to abolish the increase in firing rate of LC neurons induced by nicotine (25-200 microg/kg, i.v.). The results of the present study show that an increased concentration of endogenous brain KYNA is able to inhibit the activation of central noradrenergic neurons by nicotine. In addition, our results highlight the role of endogenous KYNA in brain as a potentially important modulator of brain glutamatergic responses. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10881031     DOI: 10.1002/1098-2396(200008)37:2<104::AID-SYN4>3.0.CO;2-L

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 4.  Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery.

Authors:  Flavio Moroni; Andrea Cozzi; Maria Sili; Guido Mannaioni
Journal:  J Neural Transm (Vienna)       Date:  2012-01-04       Impact factor: 3.575

5.  Harmane inhibits serotonergic dorsal raphe neurons in the rat.

Authors:  Khalid Touiki; Pascal Rat; Robert Molimard; Abderrahman Chait; Renaud de Beaurepaire
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys.

Authors:  Maria E Secci; Alessia Auber; Leigh V Panlilio; Godfrey H Redhi; Eric B Thorndike; Charles W Schindler; Robert Schwarcz; Steven R Goldberg; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-01-31       Impact factor: 7.853

7.  Cysteine and keto acids modulate mosquito kynurenine aminotransferase catalyzed kynurenic acid production.

Authors:  Qian Han; Jianyong Li
Journal:  FEBS Lett       Date:  2004-11-19       Impact factor: 4.124

Review 8.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.